Business Wire

Type One Energy Issues First Realistic, Unified Fusion Power Plant Design Basis

27.3.2025 17:28:00 EET | Business Wire | Press release

Share

Type One Energy announced today publication of the world’s first comprehensive, self-consistent, and robust physics basis, with conservative design margins, for a practical fusion pilot power plant. This physics basis is presented in a series of seven peer-reviewed scientific papers in a special issue of the prestigious Journal of Plasma Physics (JPP). They serve as the foundation for the company’s first Infinity Two stellarator fusion power plant project, which Type One Energy is developing for the Tennessee Valley Authority (TVA) utility in the U.S.

The Infinity Two fusion pilot power plant physics design basis realistically considers, for the first time, the complex relationship between competing requirements for plasma performance, power plant startup, construction logistics, reliability, and economics utilizing actual power plant operating experience. This Infinity Two baseline physics solution makes use of the inherently favorable operating characteristics of highly optimized stellarator fusion technology using modular superconducting magnets, as was so successfully proven on the W7-X science machine in Germany.

“Why are we the first private fusion company with an agreement to develop a potential fusion power plant project for an energy utility? Because we have a design anchored in reality,” said Christofer Mowry, CEO of Type One Energy. “The physics basis for Infinity Two is grounded in the knowledge of what is required for application to, and performance in, the demanding environment of reliable electrical generation for the power grid. We have an organization that understands this isn’t about designing a science project.”

Led by Chris Hegna, widely recognized as a leading theorist in modern stellarators, Type One Energy performed high-fidelity computational plasma physics analyses to substantially reduce the risk of meeting Infinity Two power plant functional and performance requirements. This unique and transformational achievement is the result of a global development program led by the Type One Energy plasma physics and stellarator engineering organization, with significant contributions from a broad coalition of scientists from national laboratories and universities around the world. The company made use of a spectrum of high-performance computing facilities, including access to the highest-performance U.S. Department of Energy supercomputers such as the exascale Frontier machine at Oak Ridge National Laboratory (ORNL), to perform its stellarator physics simulations.

“We committed to this ambitious fusion commercialization milestone two years ago and today we delivered,” said John Canik, Chief Science and Engineering Officer for Type One Energy. “The team was able to efficiently develop deep plasma physics insights to inform the design of our Infinity Two stellarator, by taking advantage of our access to high performance computing resources. This enabled the Type One Energy team to demonstrate a realistic, integrated stellarator design that moves far beyond conventional thinking and concepts derived from more limited modeling capabilities.”

The consistent and robust physics solution for Infinity Two results in a deuterium-tritium (D-T) fueled, burning plasma stellarator with 800 MW of fusion power and delivers a nominal 350 MWe to the power grid. It is characterized by fusion plasma with resilient and stable behavior across a broad range of operating conditions, very low heat loss due to turbulent transport, as well as tolerable direct energy losses to the stellarator first wall. The Infinity Two stellarator has sufficient room for both adequately sized island divertors to exhaust helium ash and a blanket which provides appropriate shielding and tritium breeding. Type One Energy has high confidence that this essential physics solution provides a good baseline stellarator configuration for the Infinity Two fusion pilot power plant.

“The articles in this issue [of JPP] represent an important step towards a fusion reactor based on the stellarator concept. Thanks to decades of experiments and theoretical research, much of the latter published in JPP, it has become possible to lay out the physics basis for a stellarator power plant in considerable detail,” said Per Helander, head of Stellarator Theory Division at the Max Planck Institute for Plasma Physics. “JPP is very happy to publish this series of papers from Type One Energy, where this has been accomplished in a way that sets new standards for the fidelity and confidence level in this context.”

Important to successful fusion power plant commercialization, this stellarator configuration has enabled Type One Energy to architect a maintenance solution which supports good power plant Capacity Factors (CF) and associated Levelized Cost of Electricity (LCOE). It also supports favorable regulatory requirements for component manufacturing and power plant construction methods essential to achieving a reasonable Over-Night Cost (ONC) for Infinity Two.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250327324853/en/

Contacts

Media Contact:
Andrea Schneibel, Communications Manager
Phone: +1 608-616-5965
E-mail: andrea.schneibel@typeoneenergy.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye